Mavatar Announces Early Commercial Release of Discovery
Advanced AI platform for research and pharma communities
Swedish healthtech company Mavatar, a pioneer in AI- and data-driven precision medicine, today announced an early commercial release of Mavatar Discovery - a next-generation research platform that transforms complex biological data into actionable insights at record speed.
Following extensive development and collaboration with early users, Mavatar Discovery is now being made commercially available to partners, research institutions, and pharmaceutical companies. By combining advanced AI with more than 20 years of scientific innovation, the platform makes it dramatically faster, simpler, and more reproducible to interpret transcriptomic data - a process that has traditionally taken months of manual analysis.
“The early commercial launch of Mavatar Discovery isn’t just a milestone for us - it’s a turning point for how disease research and drug discovery are done. As demand for AI-driven precision medicine accelerates, our platform gives scientists a faster path to breakthroughs while positioning Mavatar for global growth and transformative partnerships,” says Johan Juhlin, CEO and co-founder of Mavatar.
Mavatar Discovery is powered by the company’s proprietary Deep Integrated Network Analysis (DINA) framework, which integrates vast amounts of published biomedical data into a cohesive, enriched database. Large-scale analyses are performed a priori, so researchers log in to a set table of ready-to-use resources - biologically meaningful networks and context available from day one.
“With Mavatar Discovery, researchers can quickly identify biomarkers, compare disease pathways, and uncover therapeutic targets across tissues and conditions - reducing months of work to days”, says Johan Juhlin, CEO and co-founder of Mavatar
AI with Scientific Rigor
Unlike many modern AI approaches that rely on generative models, Mavatar Discovery combines symbolic AI, statistical modeling, and curated biomedical data. This ensures that every result is transparent, reproducible, and scientifically robust - a crucial differentiator for pharma and research communities.
Meet Mavatar at Biotech Week Boston 2025
Mavatar will showcase Mavatar Discovery at Biotech Week Boston 2025, September 15–18, where over 4,000 global innovators, researchers, and industry leaders from 35 countries will gather. Visit Booth 1725 for live demos and a chance to learn more about how Discovery is shaping the future of biomedical research.
To schedule a meeting or learn more, please contact:
Linda Wakeham
Chief Marketing & Communication Officer
linda.wakeham@mavatar.com
+46 730 28 3030.
About Mavatar
Mavatar is a global specialist in AI-driven precision medicine solutions for all diseases. Built on over 20 years of scientific research, Mavatar’s proprietary DINA (Deep Integrated Network Analysis) framework powers two flagship platforms: Mavatar Discovery for accelerating disease and drug research, and Mavatar Precision for delivering personalized treatment recommendations in clinical care. By creating digital twins of both patients and diseases, Mavatar enables data-driven decisions that improve treatment outcomes, optimize clinical trials, and reduce healthcare waste. Headquartered in Stockholm, Sweden, Mavatar is driving the future of truly personalized, scalable healthcare across all disease areas. We envision a future where everyone receives personalized, predictive and effective care—powered by Mavatar.
